psalexa
logo

Ornithine-Transcarbamylase Deficiency Therapeutics Pipeline Analysis

Ornithine-Transcarbamylase Deficiency Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11258
Available Format:

Ornithine-transcarbamylase deficiency is a genetic disorder which causes the accumulation of excess ammonia in the blood. Ammonia is the residual product of metabolism of protein, which is toxic in high concentration. Lack of energy, unwilling to eat, poorly controlled body temperature or breathing rate, pyloric stenosis, splenomegaly, cerebral edema, hepatic failure, and aminoaciduria are the observed symptoms of the disease. The complications associated with ornithine-transcarbamylase deficiency are intellectual disability, developmental delays, liver damage, skin lesions, and brittle hair. Ornithine-transcarbamylase deficiency generally occurs due to mutation in OTC gene which helps in synthesis of enzyme, ornithine transcarbamylase. Dimension Therapeutics, Inc. is in the process of developing scAAV8OTC gene therapy for the treatment of ornithine transcarbamylase deficiency. Translate Bio, Inc. is in the process of developing OTC drug candidate for the treatment of ornithine transcarbamylase deficiency. Some of the companies having the pipeline of ornithine transcarbamylase deficiency include Translate Bio, Inc., Dimension Therapeutics, Inc., and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry